Gastric cancer (GC) is one of the most common malignant tumors in the world. The prognosis of advanced GC is extremely poor, characterized by the high recurrence or disease progression rate after the first-line chemotherapy, and the extremely low long-term survival rate. Meanwhile, the options for subsequent treatment are limited. Studies have shown that the third-line therapy can provide significant survival benefits for selected patients with advanced GC. Currently, a series of randomized controlled trials and real-world studies related to chemotherapy, targeted therapy, and immunotherapy are conducted. In addition, the explorations of combination therapy, and screening the optimal clinical features or predictive biomarkers for the suitable population who might benefit from the third-line regimens are the hot spots for researchers. This article will provide a detailed overview of the current status and progress of the third-line treatment for advanced GC, and to illustrate the characteristics of Chinese GC treatment.
胃癌是全球最为常见的恶性肿瘤之一，晚期胃癌预后差，一线化疗后复发或疾病进展发生率高，患者生存率低，同时可选择的后线治疗手段有限。三线治疗可使经选定的晚期胃癌患者生存获益。目前，多项化疗、靶向治疗和免疫治疗相关的临床研究及真实世界研究正在开展之中。此外，联合治疗的探索、如何通过寻找临床特征或者生物学标志物筛选最佳的获益人群，也是研究者们关注的热点。文章将详细概述晚期胃癌三线治疗的现状和进展，并深入探讨中国胃癌治疗的特色。.
Keywords: Chemotherapy; Gastric neoplasms; Immunotherapy; Targeted therapy; Third-line therapy.